GI Insights CME

Jun 18 2024 11 ep. 53

This CME series focuses on improving the overall management of patients with GI disease. Faculty experts provide education that is designed to strengthen clinician skill-sets needed to provide not only better patient care —via enhanced diagnosis and management strategies—but also to optimize patient outcomes through strategies that are meant to improve therapeutic adherence.

RSS feed Share
Copy RSS


Subscribe on Podcast Addict


HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity

Feb 04 2024
Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regardin

Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers

Feb 04 2024
Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regard

What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?

Feb 04 2024
Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regardin

What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?

Feb 04 2024
Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regardin

What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers

Feb 04 2024
Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regard

Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress

Feb 04 2024
Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regardin

Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy

Apr 24 2024
Host: Yelena Janjigian, MD Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the mo

Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens

Apr 24 2024
Host: Yelena Janjigian, MD Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the mo

How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?

Apr 24 2024
Host: Yelena Janjigian, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regardin

Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference

Apr 24 2024
Host: Samuel J. Klempner, MD The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regard